---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-027346"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:55:19.279024+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q2 2023 net loss $4.7M; cash $48.0M; LP-184 IND cleared, LP-284 IND imminent

## Summary
- Cash and equivalents $48.0M at June 30, 2023 ($55.2M at Dec 2022); cash runway into 2025.
- Net loss $4.7M ($0.44/shr) vs $4.5M ($0.41/shr) in Q2 2022; R&D expenses up to $3.6M from $3.0M.
- FDA cleared IND for LP-184; Phase 1 basket trial activated for solid tumors and brain cancers.
- LP-284 IND submission expected August 2023; Phase 1 trial targeted for Q4 in non-Hodgkin's lymphomas.
- Dosed first patients in Phase 2 Harmonic trial for never-smoker NSCLC; RADR collaboration with Bielefeld University for ADCs.

## SEC filing metadata
- accession: 0001493152-23-027346
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/0001493152-23-027346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-027346
- JSON: https://secwatch.observer/filing/0001493152-23-027346.json
- Plain text: https://secwatch.observer/filing/0001493152-23-027346.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223027346/0001493152-23-027346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.